Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EUCLID: Ticagrelor vs Clopidogrel in PAD
NCT01732822Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- Dec 2012
- Primary completion
- Sep 2016
- Modality
- Small Molecules
- Countries
- 28
01
Overview
Phase 3, randomised, double-blind trial of ticagrelor in peripheral artery disease (PAD) (2 arms), sponsored by AstraZeneca. Primary endpoint: Composite of Cardiovascular Death, Myocardial Infarction, or Ischemic Stroke at 2.5 years. Started Dec 2012; status: completed.
02
Drugs
ticagrelor
03
Conditions
peripheral artery disease (PAD)
Beyond the preview
Go deeper on NCT01732822.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732822.